Thinking About Investing in Novavax (NVAX)? Know This!

Shares of Health Care sector company Novavax moved 2.7% today, and are now trading at a price of $6.99. The mid-cap stock's daily volume was 4,286,018 compared to its average volume of 9,483,668. The S&P 500 index returned a -0.0% performance.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company is based in Gaithersburg and has 1,992 full time employees. Its market capitalization is $704,814,464.

5 analysts are following Novavax and have set target prices ranging from $5.0 to $38.0 per share. On average, they have given the company a rating of hold. At today's prices, NVAX is trading -66.09% away from its average analyst target price of $20.6 per share.

Over the last year, NVAX shares have gone down by -68.0%, which represents a difference of -80.0% when compared to the S&P 500. The stock's 52 week high is $25.66 per share and its 52 week low is $5.61. Novavax has averaged free cash flows of $-228838333.3 over the last 6 years, with a mean growth rate of -26.2%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 -654,055 99,004 -753,059 -62.44
2022 -415,937 47,654 -463,591 -274.64
2021 322,946 57,486 265,460 373.21
2020 -42,541 54,622 -97,163 29.84
2019 -136,623 1,857 -138,480 25.63
2018 -184,825 1,372 -186,197
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.